Neurocrine Biosciences, Inc. (NBIX)
NASDAQ: NBIX · IEX Real-Time Price · USD
138.97
-1.12 (-0.80%)
Apr 24, 2024, 4:00 PM EDT - Market closed
Neurocrine Biosciences Stock Forecast
Stock Price Forecast
The 21 analysts with 12-month price forecasts for NBIX stock have an average target of 142.71, with a low estimate of 100 and a high estimate of 200. The average target predicts an increase of 2.69% from the current stock price of 138.97.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for NBIX stock from 22 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 7 | 7 | 7 | 7 |
| Buy | 9 | 9 | 9 | 9 | 8 | 9 |
| Hold | 6 | 6 | 6 | 6 | 6 | 6 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 21 | 21 | 22 | 22 | 21 | 22 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Hold → Buy Upgrades $140 → $170 | Hold → Buy | Upgrades | $140 → $170 | +22.33% | Apr 24, 2024 |
| Oppenheimer | Oppenheimer | Buy Maintains $200 | Buy | Maintains | $200 | +43.92% | Apr 24, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $150 | Strong Buy | Reiterates | $150 | +7.94% | Apr 24, 2024 |
| Needham | Needham | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Apr 23, 2024 |
| Wedbush | Wedbush | Buy Reiterates $147 | Buy | Reiterates | $147 | +5.78% | Apr 17, 2024 |
Financial Forecast
Revenue This Year
2.26B
from 1.89B
Increased by 19.71%
Revenue Next Year
2.63B
from 2.26B
Increased by 16.25%
EPS This Year
4.87
from 2.47
Increased by 97.14%
EPS Next Year
6.44
from 4.87
Increased by 32.26%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 2.4B | 4.0B | 3.8B | 4.1B | 4.6B |
| Avg | 2.3B | 2.6B | 3.0B | 3.3B | 3.7B |
| Low | 2.1B | 2.2B | 2.3B | 2.6B | 2.9B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 29.1% | 75.7% | 43.8% | 36.9% | 37.5% |
| Avg | 19.7% | 16.2% | 12.9% | 12.1% | 11.0% |
| Low | 11.1% | -1.9% | -10.9% | -11.3% | -13.8% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 6.01 | 8.94 | 11.94 | 15.54 | 18.48 |
| Avg | 4.87 | 6.44 | 8.65 | 12.26 | 14.29 |
| Low | 3.76 | 4.49 | 6.04 | 8.84 | 10.23 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 143.2% | 83.5% | 85.4% | 79.6% | 50.7% |
| Avg | 97.1% | 32.3% | 34.3% | 41.8% | 16.5% |
| Low | 52.4% | -7.8% | -6.3% | 2.2% | -16.6% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.